# NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/par-21-114-ninds-renewal-awards-of-sbir-phase-ii-grants/  
Official notice: https://www.grants.gov/search-results-detail/331090

> National Institutes of Health offered grants to small businesses. Applications closed on April 5, 2024.

| Field | Value |
|---|---|
| Opportunity number | PAR-21-114 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | April 5, 2024 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.853 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

## What the grant funds

Some projects initiated with SBIR or STTR funding require considerable financing beyond the SBIR/STTR Phase II award to achieve commercialization. The development of medical biotechnology products is often impeded by a significant funding gap (known as the Valley of Death) between the end of the SBIR/STTR Phase II award and the commercialization stage. The goal of this FOA is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product/technology that requires Federal regulatory approval or to bring a complex research tool to market. This opportunity aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by promoting partnerships between NINDS SBIR or STTR awardees and third-party investors and/or strategic partners in the Phase IIB competing renewal. Applicants are strongly encouraged to secure independent third-party funding throughout the Phase IIB project period.

## Questions people ask

### Is PAR-21-114 still open?

No. It closed on April 5, 2024.

### Who can apply for NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)?

Closed April 5, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under PAR-21-114?

NIH RePORTER lists 5 projects funded under PAR-21-114 in fiscal 2022 to 2026, at 5 institutions. The most were at Biocircuit Technologies, Inc., Myogene Bio, LLC, Amplo Biotechnology, Inc.

### Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before?

The largest recipients over five fiscal years were The General Hospital Corporation, The Regents of the University of California, San Francisco, The Johns Hopkins University. The program made 8,641 awards worth $9.1 billion in that time.